User profiles for K. D. Lewis

Karl Lewis

university of colorado
Verified email at ucdenver.edu
Cited by 28710

[HTML][HTML] Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib

…, D Lawrence, I Puzanov, KD Lewis… - … England Journal of …, 2012 - Mass Medical Soc
Background Approximately 50% of melanomas harbor activating (V600) mutations in the
serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032…

[HTML][HTML] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

…, FS Hodi, J Schachter, AC Pavlick, KD Lewis… - The lancet …, 2015 - thelancet.com
Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the …

[HTML][HTML] Efficacy and safety of vismodegib in advanced basal-cell carcinoma

…, MR Migden, AE Oro, L Dirix, KD Lewis… - … England Journal of …, 2012 - Mass Medical Soc
Background Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell
carcinoma. Although most basal-cell carcinomas are treated surgically, no effective …

In vivo enhancer analysis of human conserved non-coding sequences

…, M Shoukry, S Minovitsky, I Dubchak, A Holt, KD Lewis… - Nature, 2006 - nature.com
Identifying the sequences that direct the spatial and temporal expression of genes and
defining their function in vivo remains a significant challenge in the annotation of vertebrate …

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

…, GP Linette, M Milella, I Brownell, KD Lewis… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …

[HTML][HTML] PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

…, A Guminski, A Hauschild, KD Lewis… - … England Journal of …, 2018 - Mass Medical Soc
Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, …

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

GS Falchook, KD Lewis, JR Infante, MS Gordon… - The lancet …, 2012 - thelancet.com
Background MEK is a member of the MAPK signalling cascade that is commonly activated
in melanoma. Direct inhibition of MEK blocks cell proliferation and induces apoptosis. We …

Phylogenetic shadowing of primate sequences to find functional regions of the human genome

D Boffelli, J McAuliffe, D Ovcharenko, KD Lewis… - Science, 2003 - science.org
Nonhuman primates represent the most relevant model organisms to understand the biology
of Homo sapiens. The recent divergence and associated overall sequence conservation …

[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …

…, DJ DeMarini, NT Le, K Patel, KD Lewis - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for …

[PDF][PDF] Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

…, PA Ott, RK Amaravadi, KD Lewis… - Journal of clinical …, 2013 - researchgate.net
Purpose To assess pharmacodynamic effects and intrinsic and acquired resistance
mechanisms of the BRAF inhibitor vemurafenib in BRAFV600-mutant melanoma, leading to an …